secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001558370-21-015672
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress
------------------------------------------------------------------

- Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.
- Cash, equivalents and short-term investments $157.7M as of Sept 30, 2021.
- Initiated STRIDE Phase 2b trial for REN001 in PMM; completed LC-FAOD Phase 1b enrollment.
- Appointed Ashley Hall as Chief Development Officer; received US patent notice of allowance for REN001 into 2041.
- Expects Phase 1b results for McArdle disease Q1 2022 and LC-FAOD Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000155837021015672/0001558370-21-015672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000155837021015672/rphm-20211111x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-015672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer